Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

Research and Innovation Action · Running

IMMUTOL Advanced Antigen-specific Dendritic Cell-based Therapy to Re-establish Tolerance in Immune-mediated Diseases

Coordinator
Fondazione Telethon Ets, Italy
Runs
1 May 2023 to 30 April 2027
Status
Running
EU funding
€6.0m
Total cost
€6.0m
Partners
11 organisations in 5 countries
Type
Research and Innovation Action
Grant agreement
101080562

What the project is doing

In the project's own words, from its summary on CORDIS.

Autoimmune diseases are currently treated with immunosuppressive and supportive therapies, which dampen inflammation, but do not stop the cause of the disease and are required life-long. Thus, there is an unmet need for safe and effective therapies for these diseases, which are well-tolerated and targeting the cause of disease. Tolerogenic dendritic (DC) cell-based therapies, offer the possibility of restoring immune regulation leading to long-lasting effects.

Vitamin (Vit)D3-modified tolerogenic DC have been recently applied to Multiple Sclerosis (MS) patients in Phase I trials, demonstrating safety, tolerability, feasibility, and preliminary evidence of an effect. Molecular characterization of VitD3DC from MS patients suggests that they own less tolerogenic properties than those from healthy individuals. Thus, correcting these deficiencies through gene transfer could improve their effectiveness.

The aim of IMMUTOL is the fast-track development and validation of an advanced therapeutic medicinal product (ATMP) based on VitD3-modified tolerogenic DC for immunotherapy approaches. Through a multidisciplinary approach, IMMUTOL will leverage the power of tolerogenic VitD3DC-based immunotherapy to develop a more potent and durable treatment for MS and, in turn other autoimmune inflammatory diseases with an unmet medical need.

In parallel, it will bring information about tolerance mechanisms and patient-specific requirements for manufacturing effective tolDC products. Results will lead to design of a clinical protocol according to the regulatory requirements for the first-in-man application of engineered tolerogenic VitD3DC in MS patients.

Topics

Who is involved

OrganisationCityCountryRole
Fondazione Telethon EtsRomaItalyCoordinator
Klinikum Der Universitaet RegensburgRegensburgGermanyParticipant
Asociacion De Esclerosis Multiple De ToledoToledoSpainParticipant
Asphalion SLBarcelonaSpainParticipant
Institut De Investigacio En Ciencies De La Salut Germans Trias I PujolBadalona BarcelonaSpainParticipant
Institut Quimic De SarriaBarcelonaSpainParticipant
Universidad De NavarraPamplonaSpainParticipant
Syreon Kutato Intezet Korlatolt Felelossegu TarsasagBudapestHungaryParticipant
Innovation Acta SRLSienaItalyParticipant
Ospedale San Raffaele SRLMilanoItalyThird party
Stichting Sanquin BloedvoorzieningAmsterdamNetherlandsParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI